The Medical Letter on Drugs and Therapeutics
In Brief: Fentanyl Sublingual Tablets (Abstral) for Breakthrough Cancer Pain
Download PDF:   US English
Med Lett Drugs Ther. 2011 May 16;53(1364):40
 Select a term to see related articles  Abstral   Actiq   Cancer pain   Fentanyl   Fentora   Onsolis   pain 

The FDA has approved the marketing of fentanyl sublingual tablets (Abstral – ProStrakan) for treatment of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. It is the fourth transmucosal formulation of fentanyl to become available in the US for this indication.1-3

The manufacturer recommends an initial dose of 100 mcg, a maximum of 2 doses per breakthrough pain episode, and use for no more than 4 breakthrough pain episodes per day. As with all formulations of fentanyl, strong inhibitors of CYP3A4 such as clarithromycin (Biaxin, and others) or itraconazole (Sporanox, and others) can increase serum concentrations of the drug to levels that can cause respiratory depression even in opioid-tolerant patients. A single dose of any formulation of transmucosal fentanyl could be fatal for a child.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article